Elevated levels of serum S100B, a potential biomarker of BBB disruption (Blyth et al., 2009), have been observed during delirium in Alzheimer’s disease (van Munster et al., 2010) and critical illness (Hughes et al., 2016). Here, S100B is linked to Alzheimer disease.